The Analytical Scientist / Issues / 2026 / August / The Changing Role of Analytical Science in Drug Discovery
Pharma and Biopharma

The Changing Role of Analytical Science in Drug Discovery

How complex biological models, larger datasets, and laboratory automation are shaping drug discovery decisions

By James Strachan 08/27/2026 3 min read

Share

Clinical Scorecard: The Changing Role of Analytical Science in Drug Discovery

At a Glance

CategoryDetail
ConditionAnalytical Science in Drug Discovery
Key MechanismsUse of AI and automated workflows to manage data variability and enhance decision-making.
Target PopulationResearchers in drug discovery and development.
Care SettingLaboratory and research environments.

Key Highlights

  • Increased scale of data generation enhances decision-making in drug discovery.
  • Complex models introduce variability but provide valuable insights.
  • Automation improves consistency and reduces variability in assays.
  • Simpler assays can be effective early in the discovery process.
  • The right model depends on the specific scientific question.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Clinical Best Practices

          • Utilize automation to enhance data consistency and reduce variability.
          • Select models based on the specific scientific question and discovery stage.
          • Balance complexity with practicality in assay design.

          Related Resources & Content

            About the Author(s)

            James Strachan

            Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

            More Articles by James Strachan

            Recommended

            Related Content

            Loading the Molecular Dice
            Pharma and Biopharma
            Loading the Molecular Dice

            December 12, 2024

            2 min read

            How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

            CD-MS: To Megadalton and Beyond
            Pharma and Biopharma
            CD-MS: To Megadalton and Beyond

            October 1, 2024

            10 min read

            Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

            New NMR Technique Enables Direct Detection of Molecular Chirality
            Pharma and Biopharma
            New NMR Technique Enables Direct Detection of Molecular Chirality

            October 1, 2024

            1 min read

            Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

            Mass Spec Imaging Meets Proteomics
            Pharma and Biopharma
            Mass Spec Imaging Meets Proteomics

            October 2, 2024

            2 min read

            Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment